Immune response to CMV in solid organ transplant recipients: Current concepts and future directions

Expert Review of Clinical Immunology

Volumn 8, Issue 4, 2012, Pages 383-393

  Watkins, Richard R ^a,b   Lemonovich, Tracy L ^c   Razonable, Raymund R ^d  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d MAYO CLINIC   (United States)

Author keywords

adaptive immunity; antibody; CMV; innate immunity; Toll like receptor; transplantation; vaccine

Indexed keywords

CYTOMEGALOVIRUS GB VACCINE; CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MIFAMURTIDE; PLACEBO; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; B LYMPHOCYTE; CANCER RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; COLITIS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LYMPHOCYTE FUNCTION; MORTALITY; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMONIA; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID ORGAN TRANSPLANTATION; T CELL THERAPY; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOSUPPRESSION; RISK FACTORS; TRANSPLANTS; VIRAL VACCINES;

EID: 84861390163     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.25     Document Type: Review

References (96)

1. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: The national health and nutrition examination surveys, 1988-2004. Clin. Infect. Dis. 50(11), 1439-1447 (2010).
2. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: Current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 10(3), 60-65 (2003).
3. Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD. J. Exp. Med. 202(5) 673-685 (2005).
4. Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357(25), 2601-2614 (2007).
5. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. Am. J. Transplant. 8(10), 2111-2118 (2008).
6. Boeckh M, Geballe AP. Cytomegalovirus: Pathogen, paradigm, and puzzle. J. Clin. Invest. 121(5), 1673-1680 (2011).
7. Linares L, Sanclemente G, Cervera C et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant. Proc. 43(6), 2145-2148 (2011).
8. van Ree RM, De Vries AP, Zelle DM et al. Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients. Med. Sci. Monit. 17(11), CR609-CR617 (2011).
9. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med. 338(24), 1741-1751 (1998).
10. Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on long-term transplant outcome. Curr. Opin. Organ. Transplant. 15(4), 492-498 (2010).
11. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc. Natl Acad. Sci. USA 100(26), 15818-15823 (2003).
12. Mayer KD, Mohrs K, Reiley W et al. Cutting edge: T-bet and IL-27R are critical for in vivo IFN-g production by CD8 T cells during infection. J. Immunol. 180(2), 693-697 (2008).
13. 8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J. Infect. Dis. 204(11), 1663-1671 (2011).
14. 8+ T cell differentiation. J. Clin. Invest. 120(11), 4077-4090 (2010).
15. Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J. Hepatol. 2(9), 325-336 (2010).
16. Gerna G, Lilleri D, Chiesa A et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am. J. Transplant. 11(11), 2463-2471 (2011).
17. Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41(3), 237-241 (2008).
18. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: Late-onset disease and indirect consequences. Clin. Infect. Dis. 46(5), 732-740 (2008).
19. Bunde T, Kirchner A, Hoffmeister B et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 201(7), 1031-1036 (2005).
20. Abate D, Saldan A, Fiscon M et al. Evaluation of cytomegalovirus (CMV)- specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J. Infect. Dis. 202(4), 585-594 (2010).
21. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 93(2), 195-200 (2012).
22. Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 9(5), 1214-1222 (2009).
23. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 91(8), 927-933 (2011).
24. Snyder LD, Medinas R, Chan C et al. Polyfunctional cytomegalovirus- specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am. J. Transplant. 11(3), 553-560 (2011).
25. Eid AJ, Brown RA, Arthurs SK et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD. Transpl. Int. 23(5) 506-513 (2010).
26. 8+ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients. Transplant. Proc. 43(7), 2636-2640 (2011).
27. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3(12), 984-993 (2003).
28. van De Berg PJ, Heutinck KM, Raabe R et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J. Infect. Dis. 202(5), 690-699 (2010).
29. Krishnan A, Zhou W, Lacey SF, Limaye AP, Diamond DJ, La Rosa C. Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transplant. Infect. Dis. 12(4), 363-370 (2010).
30. Homs S, Mansour H, Desvaux D et al. Predominant Th1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am. J. Transplant. 9(5), 1230-1236 (2009).
31. Sester M, Sester U, Gartner B et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71(9), 1287-1294 (2001).
32. Walker JD, Maier CL, Pober JS. Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD. J. Immunol. 182(3) 1548-1559 (2009).
33. Razonable RR. Cytomegalovirus infection after liver transplantation: Current concepts and challenges. World J. Gastroenterol. 14(31), 4849-4860 (2008).
34. Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med. 6, 29 (2008).
35. Sund F, Lidehall AK, Claesson K et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: A pilot study. Clin. Transplant. 24(3), 401-409 (2010).
36. Lidehall AK, Sund F, Lundberg T, Eriksson BM, Totterman TH, Korsgren O. T cell control of primary and latent cytomegalovirus infections in healthy subjects. J. Clin. Immunol. 25(5), 473-481 (2005).
37. Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res. 157(2), 175-179 (2011).
38. Maue AC, Haynes L. CD. Gerontology. 55(5) 491-495 (2009).
39. Trzonkowski P, Debska-Slizien A, Jankowska M et al. Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD. Mech. Ageing Dev. 131(2) 96-104 (2010).
40. Humar A, Mazzulli T, Moussa G et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients. Am. J. Transplant. 5(5), 1065-1070 (2005).
41. Hughes D, Hafferty J, Fulton L et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patients. J. Clin. Virol. 41(2), 92-95 (2008).
42. Costa C, Touscoz GA, Bergallo M et al. Non-organ-specific and anti-endothelial antibodies in relation to CMV infection and acute rejection in renal transplant recipients. Clin. Transplant. 24(4), 488-492 (2010).
43. Ishibashi K, Tokumoto T, Shirakawa H et al. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors. Transplant. Infect. Dis. 13(3), 318-323 (2011).
44. Saccoccio FM, Sauer AL, Cui X et al. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 29(15), 2705-2711 (2011).
45. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin. Infect. Dis. 44(10), 1315-1320 (2007).
46. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising R, Kremers W, Razonable RR. Homozygosity for the Toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J. Infect. Dis. 205(4), 639-646 (2012).
47. Kruger B, Banas MC, Walberer A et al. A comprehensive genotype-phenotype interaction of different Toll-like receptor variations in a renal transplant cohort. Clin. Sci. (Lond.) 119(12), 535-544 (2010).
48. Lanier LL. NK cell recognition. Annu. Rev. Immunol. 23, 225-274 (2005).
49. Stern M, Elsasser H, Honger G, Steiger J, Schaub S, Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/ reactivation in kidney transplant recipients. Am. J. Transplant. 8(6), 1312-1317 (2008).
50. Hadaya K, De Rham C, Bandelier C et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am. J. Transplant. 8(12), 2674-2683 (2008).
51. Fildes JE, Walker AH, Williams SG, Yonan N, Leonard CT. CMV infection is associated with the depletion but lack of activation of peripheral blood natural killer cells in a lung transplant cohort. Transplant. Immunol. 19(3-4), 235-237 (2008).
52. Guma M, Angulo A, Vilches C, Gomez- Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104(12), 3664-3671 (2004).
53. Monsivais-Urenda A, Noyola-Cherpitel D, Hernandez-Salinas A et al. Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. Eur. J. Immunol. 40(5), 1418-1427 (2010).
54. Guma M, Budt M, Saez A et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107(9), 3624-3631 (2006).
55. 57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108(36), 14725-14732 (2011).
56. 8+ T-cell responses using QuantiFERON-CMV. Transplant. Infect. Dis. 9(2), 165-170 (2007).
57. 8+ T-cell immunity. Am. J. Transplant. 8(8), 1749-1754 (2008).
58. Lochmanova A, Lochman I, Tomaskova H et al. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant. Proc. 42(9), 3574-3577 (2010).
59. Uemura T, Riley TR, Khan A et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin. Transplant. 25(1), E32-E37 (2011).
60. Zeevi A, Husain S, Spichty KJ et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am. J. Transplant. 7(2), 471-475 (2007).
61. De Paolis P, Favaro A, Piola A et al. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. Transplant. Proc. 43(4), 1013-1016 (2011).
62. 8+ lymphocytes in patients after kidney transplantation as a marker of cytomegalovirus infection. Transplant. Immunol. 24(1), 50-56 (2010).
63. Torres-Madriz G, Boucher HW. Immunocompromised hosts: Perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis. 47(5), 702-711 (2008).
64. Witzke O, Hauser IA, Bartels M et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 93(1), 61-68 (2012).
65. Zhang LF, Wang YT, Tian JH, Yang KH, Wang JQ. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: A meta-analysis and systematic review of randomized controlled trials. Transplant. Infect. Dis. 13(6), 622-632 (2011).
66. La Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transplant. Int. 24(9), 920-931 (2011).
67. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant. 8(1), 158-161 (2008).
68. Hoffmann TW, Halimi JM, Buchler M et al. Impact of a polymorphism in the IL-12p40 gene on the outcome of kidney transplantation. Transplant. Proc. 41(2), 654-656 (2009).
69. Hoffmann TW, Halimi JM, Buchler M et al. Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation. J. Med. Genet. 47(1), 54-58 (2010).
70. Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med. 114(7), 525-531 (1991).
71. Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360(12), 1191-1199 (2009).
72. Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A Phase 2 randomised placebo-controlled trial. Lancet 377(9773), 1256-1263 (2011).
73. Gerna G, Sarasini A, Patrone M et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol. 89(Pt 4), 853-865 (2008).
74. Macagno A, Bernasconi NL, Vanzetta F et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128- 131A complex. J. Virol. 84(2), 1005-1013 (2010).
75. Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26(45), 5760-5766 (2008).
76. Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy 2(1), 117-130 (2010).
77. Schleiss MR. Cytomegalovirus vaccines: At last, a major step forward. Herpes 15(3), 44-45 (2009).
78. Bernstein DI. Vaccines for cytomegalovirus. Infect. Disord Drug Targets 11(5), 514-525 (2011).
79. Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J. Gen. Virol. 92(Pt 5), 1021-1031 (2011).
80. Zhong J, Khanna R. Delineating the role of CD. J. Gen. Virol. 91(PART 12) 2010.
81. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317(17), 1049-1054 (1987).
82. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin. Transplant. 22(1), 89-97 (2008).
83. Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81(10), 1415-1420 (2006).
84. Ranganathan K, Worley S, Michaels MG et al. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation. J. Heart Lung Transplant. 28(10), 1050-1056 (2009).
85. Snydman DR, Kistler KD, Ulsh P, Morris J. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients. Transplantation 90(12), 1432-1438 (2010).
86. Fisher RA, Kistler KD, Ulsh P, Bergman GE, Morris J. The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation. Transpl. Infect. Dis. 14(2), 121-131 (2012).
87. Brestrich G, Zwinger S, Fischer A et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am. J. Transplant. 9(7), 1679-1684 (2009).
88. Aspord C, Laurin D, Richard MJ, Vie H, Chaperot L, Plumas J. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Am. J. Transplant. 11(12), 2613-2626 (2011).
89. Harkins L, Volk AL, Samanta M et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360(9345), 1557-1563 (2002).
90. Cobbs CS, Harkins L, Samanta M et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62(12), 3347-3350 (2002).
91. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J. Virol. 86(2), 854-864 (2012).
92. Couzi L, Levaillant Y, Jamai A et al. Cytomegalovirus-induced gd T cells associate with reduced cancer risk after kidney transplantation. J. Am. Soc. Nephrol. 21(1), 181-188 (2010).
93. Couzi L, Pitard V, Sicard X et al. Antibody-dependent anti-cytomegalovirus activity of human gd T cells expressing CD16 (FcgRIIIa). Blood 119(6), 1418-1427 (2012).
94. Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 90(4), 412-418 (2010).
95. Osorio JC, Medina RD, Patino N, Ricaurte L, Moreno L, Lozano E. Significance of cytomegalovirus prophylaxis strategies and development of cancer in kidney transplant recipients. Transplant. Proc. 43(9), 3380-3382 (2011).
96. Qiu H, Straat K, Rahbar A, Wan M, Soderberg-Naucler C, Haeggstrom JZ. Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. J. Exp. Med. 205(1), 19-24 (2008).